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COMBINED CHONDROITIN SULFATE AND GLUCOSAMINE IS MORE
EFFICIENT THAN CELEBREX IN REDUCING SERUM LEVELS OF
COLL2-1, A CARTILAGE DEGRADATION BIOMARKER, IN PATIENTS
WITH SEVERE OA: RESULTS FROM A RANDOMIZED, DOUBLE-
BLIND, MULTICENTRIC CLINICAL TRIAL
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Purpose: To investigate soluble osteoarthritis (OA) biomarkers (Coll2-1,
Coll2-1NO2 and Fib3-2) in the per-protocol (PP) population of the
double-blind Multicentre Osteoarthritis interVEntion trial with Sysadoa
(MOVES) comparing the symptomatic efﬁcacy and safety of Chondroitin
Sulfate (CS) plus Glucosamine Hydrochloride (GH) versus CElecoxib
(CE) in patients with knee OA. Coll2-1 is a peptide located in the triple
helical part of type II collagen and Coll2-1NO2 is the nitrated form of
Coll2-1. Fib3-2 is a fragment of ﬁbulin-3, an extracellular glycoprotein
highly expressed in OA cartilage. The levels of these biomarkers have
been found to be elevated in serum of OA patients and to vary with
severity.
Methods: Coll2-1, mColl2-1NO2 and Fib3-2 were directly measured by
immunassays (ARTIALIS SA, Liege, Belgium) in the serum of the PP
population of the MOVES trial, which included 606 patients with knee
OA receiving 400 mg of CS plus 500 mg of GH three times daily or 200
mg of CE once daily for 6 months. This PP population included 418
subjects (215 receiving CSþGH and 203 receiving CE) with at least one
biomarker value at three time points (D0, D120 and D180).
Results: Serum biomarkers values at baseline or at follow-up D120 and
D180 were not associasted with age, sex, race, weight, height of BMI. In
overall PP population, there were no statistically signiﬁcant differences
between CE and CS þ GH groups for any of the three biomarkers at
baseline, D120 and D180. However, there was a trend in favor of CSþGH
in reducing Coll2-1 at D180 (p¼0.069) and a trend in favor of CE to
reduce Fib3-2 (p¼0.055). When population was stratiﬁed according the
radiological OA severity, the occurrence of a swelling or effusion event,
the WOMAC score or the sympromatic response to treatment some
signiﬁcant differences in biomarkers serum levels were observed
between treatment groups. At D180, CS þGH induced a signiﬁcantly
greater decrease of Coll2-1 in the subgroups of patients with the more
severe radiographic disease (K&L III), with synovitis (at least one joint
swelling or effusion event, in OMERACT-OARSI responders or in patients
with WOMAC pain at baseline  369 compared to CE (p<0.05). For
Coll2-1NO2, therewas a trend in favor of CSþ GH in the sub-population
having at least one joint swelling event during the study period
(p¼0.077) at D180. In addition, CE was more effective than CS þ GH in
reducing Fib3-2 at D180 in patients withWOMAC pain at baseline> 369
(p¼0.042).
Conclusions:CSþGHwasmoreefﬁcient thanCE in reducingserumColl2-
1, amarkerof type II collagendegradation. Thisdata indicates thatCSþGH
may down-regulate cartilage catabolism, particularly in a subgroup of
patients with severe OA. These results are in accordance with the symp-
tomatic beneﬁts observed in the clinical trials with these therapies.
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ASSOCIATIONS OF SERUM BIOMARKERS WITH RESPONSE TO SPINAL
PROCEDURES IN SUBJECTS WITH AXIAL LOW BACK PAIN
W. Huang, S. Perera, P. Jayabalan, K. Tremont, P. Coelho, J. Chamberlin,
M. Cortazzo, N. Vo, J. Kang, G. Sowa. Univ. of Pittsburgh, Pittsburgh, PA,
USAPurpose:Despite increasing numbers of interventional procedures being
performed for axial low back pain, selection criteria remain unclear and
outcomes suboptimal. Serum biomarkers represent a potential oppor-
tunity to improve clinical ability to predict response to treatment and
provide insight into mechanisms of action of procedures such as spinal
injections. The purpose of this study was to examine the association of
serumbiomarkerswithpainandpain relateddisability in individualswith
axial low back pain undergoing different spinal procedures.
Methods: Consecutive patients 18 years or older were recruited from
academic medical center departments of Physical Medicine and Reha-
bilitation and Anesthesiology who had already consented for either
epidural steroid injection (ESI, n¼48) or medial branch block without
steroid (MBB, n¼45) as part of their routine clinical care. Subjects were
eligible if they had primarily axial low back pain that was more severe
than pain in any other part of the body, and did not have radiation of
pain into the lower extremities, red ﬂags of serious underlying illness
(such as fever, weight change, bowel or bladder changes or neurologic
decline), recent oral steroids, uncontrolled psychiatric illness, or sys-
temic inﬂammatory conditions.
Serum blood samples were taken immediately prior to the procedure
and at clinical follow-up and assayed for Neuropeptide Y, E-selectin,
RANTES, CS846, CTXII, and serotonin. Responders to injection were
deﬁned as improvement in pain score of 2 points or more on a 0-10
numeric pain rating scale (immediately following the procedure for
MBB, and at follow-up for ESI). Gender, age, race, education, employ-
ment status, smoking status, Oswestry disability index, Roland Morris
Disability, McGill Pain Questionnaire, Generalized Anxiety, PHQ-9,
walking speed, fear avoidance beliefs, catastrophizing, cumulative ill-
ness rating scale, prior treatments and exercise, treatment expectation,
and medications were also collected. Wilcoxon rank sum and Fisher’s
exact tests were used for comparing responders and non-responders.
Results: Response rates were 78% and 48% for MBB and ESI, respec-
tively. Among subjects undergoing MBB, responders had higher base-
line RANTES levels than non-responders (p¼0.04). Among subjects
undergoing ESI, responders had lower baseline CS846 levels (p¼0.04),
greater frequency of past exercise (p¼0.04), and greater percentage
expecting relief (p¼0.04) than non-responders. No other associations
were observed with other baseline clinical variables.
Among subjects undergoing MBB, serotonin concentrations increased
pre- to post-procedure in non-responders and decreased in responders
(responder to non-responder difference p¼0.048). Among subjects
undergoing ESI, E-selectin showed a tendency toward more decreased
levels post-procedures in responders (p¼0.1).
Conclusions: These data identify candidate serum biomarkers that may
have utility for patient selection for spinal procedures. Because clinical
decision making for interventional management for axial low back pain
is even more challenging than for radiculopathy, these represent
important biomarkers for use in prospective studies to assess and val-
idate their predictive ability. In addition, the associated biomarkers may
provide useful insight into the mechanism of spinal procedures by
identifying important targets for future study. Larger studies are needed
to conﬁrm the utility of these identiﬁed biomarker candidates.
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IDENTIFICATION AND CLINICAL CHARACTERIZATION OF
BIOMARKERS DESCRIBING JOINT INFLAMMATION
A.C. Bay-Jensen y, A. Valdes z, I. Byrjalsen y, M.A. Karsdal y, N. Arden x.
yNordic BioSci. A/S, Herlev, Denmark; zUniv. of Nottingham, Nottingham,
United Kingdom; xUniv. of Oxford, Oxford, United Kingdom
Purpose: A proportion the osteoarthritis (OA) patients experience joint
inﬂammation with associated pain and discomfort. However to present
day, there are limited objective measures available for monitoring and
identify those patients who have inﬂammatory OA. The aim of this
study was study the association between joint inﬂammation and bio-
markers associated with connective tissue inﬂammation and cartilage
degradation.We used four biomarkers that have previously been shown
to be associated with inﬂammation and joint destruction.
Methods: Biomarkers were measured in 288 women and 186 menwith
OA and mean age of 64.2 year (SD 7.6) from the VIDEO cohort. Knee
effusion, clinical signal of synovitis and WOMAC pain, stiffness and
function, and ESR were recorded for each patient. Serum levels of the
connective tissue biomarkers C3M and CRPM (type III collagen and C-
reactive protein neo-epitopes, Nordic Bioscience), urinary CTX-II/crea-
tinin [IDS PLC] (type II collagen neo-epitopes) and serum COMP
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were log-transformed and correlations were assessed by Pearson’s r2
and by multivariate correlation adjusting for age, gender and BMI.
Results: In the univariate correlation only COMP and CTX-II were cor-
related with Age (r2¼0.16, p¼0.0005, r2¼0.14, p¼0.004), and CTX-II
with age (r2¼0.13, p¼0.005). C3M and CRPM were signiﬁcantly corre-
lated to ESR (r2¼0.12, p¼0.007, r2¼0.23, p<0.0001). CTX-II were sig-
niﬁcantly correlated with WOMAC function and stiffness (r2¼0.17,
p¼0.0003, r2¼0.17, p¼0.0003). There was a gender dependency seen
for WOMAC scores, ESR and CTX-II (p<0.05), as well as a signiﬁcant
correlation between BMI, WOMAC and ESR (p<0.01). The multivariate
regression was adjusted accordingly. C3M and CRPM remained asso-
ciated with ESR (p¼0.043, p<0.0001). CRPM was associated with
WOMAC pain (p¼0.05) and signiﬁcantly associated with WOMAC
stiffness (p¼0.040). CTX-II was signiﬁcantly associated with WOMAC
stiffness (p¼0.003) and function (p¼0.023). In addition, CRPM was
signiﬁcantly higher in patients with clinical signal of synovitis (9.4[9.1-
9.6] versus 11.3[9.8-13.0], p¼0.004). Patients with a high CRPM level
had an odd ratio of 4.2 [1.6-11], p¼0.005, of having clinical signal of
synovitis when adjust for age, gender and BMI.
Conclusions: The aim was to investigate whether biomarkers of con-
nective tissue degradation and inﬂammation as well of cartilage deg-
radation were associated with clinical measures of inﬂammation. The
results show that especially one biomarker, CRPM, was associated with
different measures normally associated with joint inﬂammation. This
suggests that CRPM could be sensitive, non-invasive and objective
marker of joint inﬂammation. This study was funded by the TreatOA
consortium as well as the Danish research foundation.
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N-PROPEPTIDE OF COLLAGEN IIA (PIIANP) AS A MARKER OF
OSTEOARTHRITIS BURDEN
H.N. Daghestani y, J.M. Jordan z, M. Doherty x, A. Wilson k, V.B. Kraus y.
yDuke Univ., Durham, NC, USA; z The Univ. of North Carolina at Chapel
Hill, Chapel Hill, NC, USA; x The Univ. of Nottingham, Nottingham, United
Kingdom; kUniv. Coll. Dublin, Dublin, Ireland
Purpose: Osteoarthritis (OA) is a direct result of cartilage degradation
and its irreversible loss. Cartilage homeostasis relies on the controlled
catabolism ofmatrix proteins such as collagen and the replacementwith
newly synthesized proteins by chondrocytes. Type II collagen is the
major type of collagen in articular cartilage and is synthesized as a pro-
collagen with propeptide domains. In particular, the N-propeptide of
collagen IIA (PIIANP) has been considered a marker for cartilage turn-
over. In fact, serum levels of PIIANPhavebeen reported tobe signiﬁcantly
decreased in patients with knee osteoarthritis and rheumatoid arthritis,
when compared to healthy controls, reﬂecting decreased synthesis of
collagen in patients with arthritis. The goal of this study was to evaluate
PIIANP as a marker of burden of disease in various joints.
Methods: We evaluated 1235 patients from the Genetics of Generalized
Osteoarthritis (GOGO) study. This cohort consisted of 243 Caucasianmen
and 992 Caucasian women, age range 37-92 years (mean 65.4 ± 9.0 SD)and bodymass index (BMI) range 14.9e61.7 kg/m2 (mean 28.8 ± 6.3 SD).
Serum PIIANP was diluted 10-fold and measured using a competitive
enzyme-linked immunosorbent assay (EMD Millipore Corporation, Mis-
souri,USA)witha sensitivity limitof17.2ng/mL.Anyosteophyte (OST)and
joint space narrowing (JSN) or disc space narrowing (DSN) were scored
bilaterally from radiographs and scores were summed by joint site based
on the number of measurable joint faces. The OA burden scores were
normalized to the possiblemaximal scores by joint site as follows: knees 4
JSN, 8 OST; hips 6 JSN, 8 OST; hands 30 JSN, 30 OST; and lumbar spine 5
DSN,10 OST. The PIIANP concentrations were log transformed so that the
data would be normally distributed. Multivariable linear regression
modelswere used to assess the association of serum PIIANPwith OSTand
JSN/DSN burden of knee, hip, spine, and hand radiographic OA. Models
included all joint sites and disease features with backward stepwise
selection of variables. Models were also adjusted for covariates of age,
gender, and BMI; P-values  0.05 were considered signiﬁcant.
Results: Serum PIIANP concentrations measured in the GOGO cohort
ranged between 86.9 - 24023.1 ng/mLwith ameanvalue of 3800.1 ng/mL.
The overall inter-assay coefﬁcient of variation was 9.6% (N ¼ 19 plates).
SerumPIIANPwas not associatedwith age, gender, nor BMI. Radiographic
JSN data were available for 1235 patients, while OST data were available
for 1233participants. The frequencyof radiographicOA ranged froma low
of 24.7% for any hip JSN to a high of 96.4% for any handOST. Serum PIIANP
was negatively associated with knee OST burden (parameter estimate b:
-0.155, P < 0.0001 adjusted for covariates and knee JSN). Serum PIIANP
wasalsonegativelyassociatedwithhip JSN (b: -0.169, P<0.0001, adjusted
for covariates and hip OST). Although serum PIIANP was positively asso-
ciated with both spine DSN (b: 0.183, P < 0.0001, adjusted for covariates)
and spine OST burden (b: 0.204, P: < 0.0001, adjusted for covariates),
serumPIIANPwas positively associatedwith only spineOST burdenwhen
adjusted for DSN (b 0.179, P: < 0.0001, adjusted for covariates). There was
no association between PIIANP and the burden of hand OA.
Conclusions: Serum PIIANP representing collagen synthesis, was lower
in patients with greater burden of hip and knee OA. Conversely, serum
PIIANP was greater in patients with a higher burden of spine OA. These
results are consistent with a prior study that showed that high serum
PIIANP was especially associated with spine disease (facet arthritis and
presence of disc degeneration e lumbar OST not scored) but also hand
radiographic OA. In our study, prior to adjustment for OST, DSN alone
was signiﬁcantly associated with serum PIIANP but OST proved to be
the independent predictor of the biomarker level rather than DSN.
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POLYAMINES IN OSTEOARTHRITIS
F. Saunders, J.S. Greogory, R.J. Barr, R.M. Aspden. Univ. of Aberdeen,
Aberdeen, United Kingdom
Purpose: Polyamines are ubiquitous polycationic molecules found in all
mammalian cells. They are involved in the regulation of cellular pro-
liferation and levels are elevated in tissues undergoing more rapid
proliferation, such as in cancer cells. In early osteoarthritis (OA) there is
increased proliferation as a response to damage repair. Therefore
polyamines could be a useful marker of this increased proliferation and
OA progression. The purpose of this study was to determine whether
there were differences in polyamine concentrations in a cohort of vol-
unteers with various radiographic grades of hip or knee OA.
Methods: Polyamine concentrations were determined by LC-MS/MS
using a benzoyl chloride derivatisation method from plasma samples
(n¼57 knee & n¼30 hip). Kellgren-Lawrence grade (KLG) was assessed
from radiographs by a single clinician. OA severity groups were deter-
mined by KLG groupings (KLG¼0, both knees/hips or KLG¼1 in one
knee/hip & KLG¼0 for contralateral knee/hip; no OA; KLG¼1 in both
knees/hips, mild OA; KLG¼2, moderate OA; KLG¼3-4 severe OA).
Radiographic OA (ROA) was deﬁned as KLG 2. Plasma concentrations
of plasma analytes were tested using one-way ANCOVA, weighted for
OA severity with polynomial contrasts and adjusted for age & BMI.
Analysis of ROA v no ROA was analysed using independent sample t-
tests. All tests were performed using SPSS v22.0.
Results: Our data show that the determination of plasma polyamine
concentrations is reliable with intra-assay variation % RSD calculated to
be 9.6 (Putrescine; PUT), 7.2 (Spermidine; SPD), 8.4 (Spermine; SPM)
and the inter-assay variation was 8.7 (PUT), 7.9 (SPD) & 9.6 (SPM).
Analysis of the polyamines in plasma by two way ANCOVA for joint
affected and OA severity ﬁltered to exclude the no OA group, showed
that there was a statistically signiﬁcant interaction for PUT
